We previously showed that the EP2 knockout mice were resistant to chemically induced skin carcinogenesis. The purpose of this study was to investigate the role of the overexpression of the EP2 receptor in mouse skin carcinogenesis. To determine the effect of overexpression of EP2, we used EP2 transgenic (TG) mice and wild-type (WT) mice in a DMBA (7,12-dimethylbenz[a]anthracene)/TPA (12-O-tetradecanoylphorbol-13-acetate) twostage carcinogenesis protocol. EP2 TG mice developed significantly more tumors compared with WT mice. Overexpression of the EP2 receptor increased TPAinduced keratinocyte proliferation both in vivo and in vitro. In addition, the epidermis of EP2 TG mice 48 h after topical TPA treatment was significantly thicker compared to that of WT mice. EP2 TG mice showed significantly increased cyclic adenosine monophosphate levels in the epidermis after prostaglandin E2 (PGE2) treatment. The inflammatory response to TPA was increased in EP2 TG mice, as demonstrated by an increased number of macrophages in the dermis. Tumors and 7 Â TPA-treated and DMBA-TPA-treated (6 weeks) skins from EP2 TG mice produced more blood vessels than those of WT mice as determined by CD-31 immunostaining. Vascular endothelial growth factor (VEGF) protein expression was significantly increased in squamous cell carcinoma (SCC) samples from EP2 TG mice compared that of WT mice. There was, however, no difference in the number of apoptotic cells in tumors from WT and EP2 TG mice. Together, our results suggest that the overexpression of the EP2 receptor plays a significant role in the protumorigenic action of PGE2 in mouse skin.
Introduction
Constitutive overexpression of cyclooxygenase 2 (COX-2) has been observed in skin tumors as well as other types of cancer (Cao and Prescott, 2002) . The protumorigenic role of COX-2 related to tumor development has been demonstrated in experimental murine models of skin cancer (Mu¨ller-Decker et al., 1995) . Both genetic deletions of COX, nonspecific COX inhibitory nonsteroidal anti-inflammatory drugs (NSAIDs), or COX-2-specific inhibitors prevent skin tumor development following a DMBA (7,12-dimethylbenz[a] anthracene)-TPA (12-O-tetradecanoylphorbol-13-acetate) protocol or UV irradiation (Furstenberger et al., 1989; Fischer et al., 1999; Cao and Prescott, 2002; Tiano et al., 2002) . Collectively, the results from these studies show that COX-2 plays an important role in skin cancer development.
Prostaglandin E2 (PGE2) is the major prostaglandin produced by COX-2 in the skin (Conconi et al., 1996) . We previously showed that PGE2 induces keratinocyte proliferation in vitro (Sung et al., 2005) . Additionally, it has been demonstrated that PGE2 increased VEGF expression via a cyclic adenosine monophosphate (cAMP)-dependent mechanism (Hoper et al., 1997) and was shown to play an antiapoptotic role in several tissues (Lu et al., 1995; Sheng et al., 1998; Ueda et al., 2001; Nishihara et al., 2003) . Prostaglandin E2 can bind to four different transmembrane receptors (EP1, EP2, EP3 and EP4), which are linked to several signaling pathways. Using knockout mice, we recently reported that the EP2 receptor, but not the EP3 receptor, plays a significant role in the protumorigenic action of PGE2 in skin tumor development (Sung et al., 2005) . However, it was unknown whether the expression level of EP2 changed during TPA promotion or UV carcinogenesis, as well as whether increasing EP2 expression contributes to skin tumor development. To address these questions, we generated EP2 TG mice in which the human EP2 cDNA is under the control of the bovine keratin 5 (BK5) promoter. EP2 receptor is primarily overexpressed in these TG mice in the basal layer of the epidermis where the BK5 promoter is most active. We hypothesized that the overexpression of the EP2 receptor would contribute to skin tumor development through the induction of proliferation, angiogenesis and inhibition of apoptosis. Here, we report that the overexpression of EP2 enhances skin tumor development and proliferation, angiogenesis and inflammation in mouse skin.
Results
EP2 expression in mouse skin keratinocytes and activation of EP2 in mouse skin tumor promotion To understand the effect of EP2 activation on mouse skin carcinogenesis, EP2 expression levels in mouse skin were first determined by real-time polymerase chain reaction (PCR) and Western blot. As shown in Figure 1a , at the mRNA level, EP2 expression is upregulated more than five fold at 6 h following a single treatment with TPA and from 6 to 18 h following the last of four treatments with TPA. In both papillomas and carcinomas, EP2 was upregulated by at least 15-fold over acetone treated skin. In addition, Western blot analysis showed that EP2 expression was elevated in skin papillomas and carcinomas from a DMBA-TPA tumor study compared to that in normal skin (Figure 1b) . The results from our previous study showed that EP1, EP3 and EP4 were also expressed in murine epidermis, and that TPA upregulates the expression only of the EP2 receptor (Sung et al., 2005) . These data led us to hypothesize that EP2 activation may be an early and critical event, leading to development of skin papillomas and carcinomas. Therefore, we focused on the role of EP2 activation during mouse skin tumor promotion.
Characterization of bovine keratin 5.EP2 transgenic mice A diagram of the BK5.EP2 transgene is shown in Figure 2a . The construct used to generate EP2 TG mice contains 5.2 kb of the BK5 promoter, 0.6 kb rabbit b-globin second intron, 1.1 kb human EP2 cDNA, flag tag and B1 kb with rabbit b-globin poly A and the SV40 poly A sequence. The TG line showing the highest level of expression was used for this study, although progeny from two other founders showed similar skin phenotypes. Western blot analysis showed that protein expression of EP2 from epidermis of TG mice was Western blot of proteins from normal skin (three individual FVB mice) and papillomas and carcinomas produced from a DMBA-TPA study immunostained with an antibody against EP2. Papillomas and carcinomas of similar size produced from randomly selected mice were used. N -normal skin (FVB). P -benign papillomas. C -squamous cell carcinomas. PC -positive control (epidermis of EP2 TG mice). Loading control was represented by Coomassie Blue-stained gel.
higher than that of wild-type (WT) mice (Figure 2b ). Histological analysis of skin from adult WT FVB and EP2 TG mice showed that the skin of EP2 TG mice was not morphologically altered compared to that of WT mice ( Figure 2c ). EP2 receptor-dependent signaling can induce an increase in cAMP levels (Hoper et al., 1997) . In our previous study, PGE2 failed to induce cAMP production in the epidermis of EP2 knockout mice (Sung et al., 2005) . As predicted, EP2 TG mice had significantly increased cAMP levels after topical PGE2 treatment ( Figure 2d ). SQ 22 536, an adenylate cyclase inhibitor with PGE2 cotreatments also decreased cAMP levels compared to PGE2 treatment alone in TG mice. This suggests that the Gs-coupled EP2 receptor can induce cAMP production and cAMP-dependent PKA signaling, which may affect the expression of target genes related to cell proliferation, apoptosis and angiogenesis, culminating in enhanced tumorigenesis.
Overexpression of EP2 enhanced skin tumor development
To test the role of the overexpression of EP2 receptor in mouse skin carcinogenesis, we used EP2 TG mice and WT (FVB strain) in a DMBA/TPA two-stage carcinogenesis protocol. The EP2 TG mice had considerably more tumors (Figure 3a ) and squamous cell carcinoma (SCC) (Figure 3b ) compared to WT mice. At 28 weeks the mean number of tumors/mouse was 6.9 for WT and 9.4 for EP2 TG mice. At 28 weeks the cumulative total number of SCC was five for WT and 15 for EP2 TG mice. However, tumor incidence of EP2 TG mice was similar to that of WT mice (Figure 3c ). The distribution of tumor size in EP2 TG mice was similar to that of WT mice in the medium size category (2-5 mm). However, EP2 TG mice produced much larger size (BX5 mm) tumors and fewer small size (p2 mm) tumors than WT mice (data not shown). As shown in Figure 3d by Western blot analysis, EP2 expression was upregulated in both papillomas and carcinomas from EP2 TG mice compared to WT mice. The higher level of expression of EP2 in the tumors from EP2 TG mice is likely to be due to both endogenous EP2 and transgene expression, as determined by the expression of flag tag. These data suggest that the EP2 receptor may have a significant contribution to skin tumor development and progression.
Overexpression of EP2 causes increased cell proliferation and hyperplasia in response to 12-O-tetradecanoylphorbol-13-acetate To determine whether overexpression of EP2 in mouse epidermis affects cell proliferation, we performed 5-bromo-2-deoxyuridine (BrdU) incorporation assays and 3 H-thymidine incorporation assays in vivo and in vitro using EP2 TG mice and WT control mice. Our data showed that overexpression of the EP2 receptor causes an increase in cell proliferation in both vehicle control and TPA-treated mice (EP2 TG 64.873.0% vs WT 4971.3%; Po0.001) (Figure 4a ). We next examined whether the overexpression of the EP2 receptor could affect TPA-induced epidermal hyperplasia. Our data showed that epidermal thickness of EP2 TG mice was significantly increased compared to that of WT mice 48 h after TPA treatment (EP2 TG 35.970.7 mm vs WT 25.371.4 mm; Po0.001) (Figure 4b and proliferation and PGE2 response in vitro ( Figure 4d ). This suggests that the proliferative response of keratinocytes to PGE2 is not dependent on factors from the dermis. Overexpression of EP2 causes increased angiogenesis, but no effect on keratinocyte apoptosis. We hypothesized that overexpression of the EP2 receptor could induce vascularization. Macroscopic inspection of the dermis of EP2 TG mice showed increased vascularization compared to that in WT mice ( Figure 5a ). This was also seen at the microscopic level, using CD-31 immunostaining of endothelial cells, and occurred in both TPA-treated and DMBA-TPA treated skins ( Figure 5b ). To determine whether the extent of tumor angiogenesis or apoptosis correlates with the enhanced tumor numbers in the EP2 TG mice, we immunostained papillomas and malignant SCC samples of similar sizes from EP2 TG and WT mice with an anti-CD31 antibody or an anticaspase-3 antibody respectively. Significant differences in blood vessel number were observed between SCC from WT and EP2 TG mice (108.3716.9 for WT vs 14375.5 for EP2 TG, Po0.001) (Figure 5c ). However, there was no difference between WT and EP2 TG mice in CD-31 stained papillomas. Western blot analysis was performed to determine whether the overexpression of the EP2 receptor upregulates VEGF expression during tumor development. Vascular endothelial growth factor protein expression was significantly increased in SCC samples from EP2 TG compared to that of WT mice ( Figure 5d) ; there was no difference of VEGF expression observed in papillomas between WT and EP2 TG mice (data not shown). As for apoptotic cells, there was also no difference observed in tumors from WT and EP2 TG mice using an antibody against caspase-3 (data not shown). These data suggest that alterations in angiogenesis, but not apoptosis, could explain the observed differences in tumor growth between WT and EP2 TG mice.
Overexpression of EP2 affects 12-Otetradecanoylphorbol-13-acetate-induced inflammation
To determine whether overexpression of the EP2 receptor alters the inflammatory response to TPA, we immunostained the skins of EP2 TG mice and WT mice 48 h after acetone or TPA treatment with an antibody against a macrophage marker. In our previous study, the number of macrophages was significantly reduced after TPA treatment in the skins of EP2 knockout mice compared to that in WT mice. As predicted, overexpression of the EP2 receptor significantly increased TPA-induced inflammation in mouse skin (42.575.1 for WT vs 66.272.4 for EP2 TG, Po0.01) (Figure 6 ). The increased inflammation in EP2 TG mice may also contribute to the observed differences in tumor development between WT and EP2 TG mice.
Discussion
In this study, we showed the EP2 receptor was elevated in mouse skin tumors. Therefore, we used BK5.EP2 TG mice as one approach to determining whether increased expression of the EP2 receptor contributed to skin carcinogenesis. We recently showed that EP2 receptor played a significant role in the protumorigenic action of PGE2 in skin tumor development using EP2 knockout mice (Sung et al., 2005) . We have shown that deletion of the EP2, but not the EP3 receptor, for PGE2 resulted in suppression of skin tumor development and was associated with decreased proliferation, angiogenesis, inflammation and cell survival (Sung et al., 2005) . Our current results are in agreement with this previous study in that EP2 TG mice showed an enhancement in cell proliferation compared to WT mice after a single TPA treatment in vivo. In vitro, primary keratinocytes cultured from EP2 TG mice also showed an increased proliferation response to PGE2. Additionally, epidermal thickness of EP2 TG mice was significantly increased compared to that of WT mice after TPA treatment. This suggests that the major proliferative activity of the EP2 receptor occurs in the epidermis rather than in mesenchymal or other tissues. Previous reports also showed that the EP2 receptor was involved in angiogenesis in several cancer tissues including colon and mammary gland (Sonoshita et al., 2001; Chang et al., 2004 Chang et al., , 2005a . Specifically, the EP2 receptor was involved in induction of intestinal polyp angiogenesis and growth (Seno et al., 2002) . Recently, one group showed that PGE2-mediated VEGF expression was regulated by EP2 receptor in mouse mammary tumor cells (Chang et al., 2005b) . In this study, we showed that overexpression of the EP2 receptor resulted in induction of vascularization and enhancement of VEGF expression in SCC from EP2 TG mice. Additionally, one group demonstrated that PGE2 increased VEGF expression via a cAMP-mediated mechanism (Hoper et al., 1997) . The EP2 TG mice have increased cAMP levels after PGE2 treatment. Thus, our data are in agreement with a model in which PGE2 elevates cAMP levels through EP2 activation, which in turn induces VEGF and angiogenesis. Prostaglandin E2 has an anti-apoptotic role in normal and cancer cell lines (Sheng et al., 1998; Ueda et al., 2001; Nishihara et al., 2003) . Our previous study showed that tumors from WT mice produced fewer apoptotic cells than those of EP2 knockout mice. However, unexpectedly, here, the EP2 TG mice were not different from WT mice with regard to apoptotic cells. Whether this is due to differences in the background strain of the mice or targeted vs whole animal alteration of EP2 is unknown. Six to 8-week-old female homozygous EP2 TG mice and WT mice were initiated topically on dorsal skin with 100 mg with DMBA in 200 ml of acetone (six each per treatment group). At 2 weeks after initiation, the mice were topically treated with 2.5 mg TPA in 200 ml acetone twice a week for a period of 6 weeks. Groups of six mice per treatment group were treated three times weekly for 2 weeks and killed 48 h after a single treatment of 2.5 mg of TPA to get 7 Â TPA-treated skin. The number of CD31 vessels was counted in 15 fields per section at a magnification of Â 400. *Po0.001 vs WT. (c) Effect of EP2 overexpression on vascularization in squamous cell carcinoma (SCC). Eight fields ( Â 400 magnification) were counted for each papilloma and SCC of similar size from WT and EP2 TG mice. Data from five papillomas and five SCC from WT and EP2 TG mice are presented and values are means7s.d., *Po0.05 vs WT. (d) Effect of EP2 overexpression on vascular endothelial growth factor (VEGF) expression in SCC from WT and EP2 TG mice. Western blot of proteins from SCC produced from the DMBA-TPA study stained with antibody against VEGF. PC -positive control. Loading control is represented by b-actin.
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Topical TPA has been well demonstrated to induce inflammation in skin (Fischer et al., 1990 ) and inhibition of inflammation inhibits skin tumor development (Fischer et al., 1990) . Our recent studies showed that the EP2 ablation reduced TPA-induced inflammation in mouse skin as measured by the number of macrophages in the dermis (Sung et al., 2005) . Here, we showed that overexpression of the EP2 receptor was involved in enhancement of TPA-induced inflammation. Taken together, the EP2 receptor, at least partially, plays an important role in TPA-induced inflammation in skin. There are several possible mechanisms through which elevated EP2 may enhance inflammation, including an influx of macrophages. Previous studies showed that interleukin-1a (IL-1a), a primary proinflammatory cytokine, can be induced by PGs (Murphy et al., 2003) . Our previous study showed that induction of IL-1a was significantly reduced in EP2 knockout mice compared to WT mice (Sung et al., 2005) . Collectively, this suggests that the enhancement of inflammation in EP2 overexpressing mice is via upregulated cytokine production.
Our results strongly suggest that PGE2 produced by COX-1/2 has biological effects (e.g., proliferation, angiogenesis, apoptosis and inflammation) that are mediated by the EP2 receptor in this mouse model. Additional studies are needed to determine the downstream target genes and transcription factors involved in the EP2 receptor-mediated signaling pathway. It has been demonstrated that CREB plays an important role in inducing proliferation and angiogenesis and apoptosis in other tissues (Desdouets et al., 1995, Shaywitz and Greenberg, 1999) . Anti-apoptotic genes (e.g., bcl-2 and IAP), VEGF, cell cycle genes (e.g., cyclin D1 and cyclin A) are known to be regulated by CREB via a functional CRE (20, 21) . It was suggested that CREB might also play a role in tumor progression (Desdouets et al., 1995; Shaywitz and Greenberg, 1999) . We suggest that EP2-induced PKA signaling resulting in proliferation, angiogenesis and inflammation are a major part of the underlying mechanisms of the promotion stage of mouse skin carcinogenesis. However, several studies have shown that activation of the PGE2/cAMP/PKA pathway upregulated amphiregulin (AR), a ligand for the epidermal growth factor receptor (EGFR), which transduced mitogenic signals in colon cancer cells (Shao et al., 2003 (Shao et al., , 2004 . Epidermal growth factor receptor signaling results in AP-1 activation, which has been shown to regulate keratinocyte proliferation (Suzukawa et al., 2002; Young et al., 2003) . Thus, it is possible that the mechanism by which EP2 activation increases cell proliferation involves both CREB and AP-1. Further studies are needed to elucidate the role for these two transcription factors in PGE2-induced cell proliferation.
Based on previous studies, the EP1 and EP4 receptors also play an important role in colon carcinogenesis (Watanabe et al., 1999; Mutoh et al., 2002; Kitamura et al., 2003; Kawamori et al., 2005) . Deletion of the EP1 and EP4 receptors resulted in inhibition of azoxymethane (AOM)-induced colon cancer development in EP1 and EP4 knockout mice (Watanabe et al., 1999; Mutoh et al., 2002; Kitamura et al., 2003; Kawamori et al., 2005) . This suggests that the EP1 and EP4 receptors may also have protumorigenic action in skin carcinogenesis. Further studies are needed to determine the roles of the EP1 and EP4 receptors in skin carcinogenesis and their role in induction of proliferation, angiogenesis, apoptosis and inflammation in skin.
In summary, we have shown that the overexpression of the EP2 receptor for PGE2 results in enhancement of skin tumor development and is associated with increased proliferation, angiogenesis and inflammation. Overexpression of COX-2 in tumors, a common phenomena (Cao and Prescott, 2002) , leads to increased production of PGE2 which activates the EP receptors. The activation of the EP receptors in turn culminates in the upregulation of target genes that promotes angiogenic and tumorigenic processes. Our results presented here provide mechanistic insight as to why COX-2 overexpression can enhance tumorigenic potential. In light of the disclosure of the undesirable cardiovascular side effects of COX-2 inhibitors (Solomon et al., 2005) , our results further suggest that EP receptors may be attractive therapeutic and chemopreventive targets. enzyme immunoassay system (Perkin-Elmer Life Sciences), PGE2 (Cayman Chemical CO., Ann Arbor, MI, USA), SQ 22 536 (Sigma Chemical Co., St Louis, MO, USA), anticaspase-3 antibody (R&D Systems, Minneapolis, MN, USA), EP2 antibody (Cayman Chemical Co.), anti-flag antibody (Sigma Chemical Co.), sheep anti-mouse immunoglobulin Gconjugated horseradish peroxidase (Amersham Biosciences, Piscataway, NJ, USA), VEGF antibody (Sigma Chemical Co.), goat anti-rabbit-immunoglobulin G-conjugated horseradish peroxidase and b-actin antibody (Santa Cruz BioTechnology), rabbit anti-mouse antibody (Accurate Chemical and Scientific Corp., Westbury, NY, USA), goat anti-rabbit IgG antibody (Vector company, Burlingame, CA, USA), donkey anti-goat HRP antibody (Santa Cruz BioTechnology), chemiluminescence detection system (ECL; Perkin-Elmer Life Sciences) and antimacrophage antibody (F4/80 Macrophage, Serotec, UK) were used.
Materials and methods

Materials
Real-time polymerase chain reaction For determining expression of the EP2 receptor in single and 4 Â TPA-treated epidermis and tumors (five DMBA-TPAinduced papillomas and four SCC samples were used) by realtime PCR, total RNA was isolated from the epidermis or the tumors using Tri-reagent (MRC, Cincinnati, OH, USA) following the manufacturer's protocol. RNA was extracted and purified using the RNeasy Mini protocol for RNA clean up (Qiagen, Valencia, CA, USA). The quality of RNA was checked by on-chip gel electrophoresis (Agilent 2100 Bioanalyzer, Palo Alto, CA, USA). From the RNA samples, the cDNA was synthesized by reverse transcription of 1 mg of RNA with 100 units MMLV-reverse transcriptase (Ambion Company, Austin, TX, USA) in the presence of 50 mM random decamers and 2.5 mM dNTPs (Ambion Company). In the mouse EP2 cDNA-specific real-time quantitative PCR assay, the reaction mixture contained 1.25 ml of EP2 mouse primer and probe mixture (Applied Biosystems, Foster, CA, USA), 12.5 ml TaqMan Universal PCR Master Mix (Applied Biosystems), and 2 ml of cDNA, in a total volume of 25 ml. After enzyme activation for 10 min at 951C, 40 two-step cycles were performed (15 s at 951C and 60 s at 601C) by ABI PRISMt 7700 Sequence Detection System (Applied Biosystems). Each sample was amplified in triplicate. Ras cDNA-specific realtime quantitative PCR assay was used for normalization. The reaction mixture contained 12.5 ml TaqMan Universal PCR Master Mix (Applied Biosystems), 0.75 ml Ras mouse forward primer or reverse primer (Applied Biosystems), 0.25 ml Ras mouse probe (Applied Biosystems) and 2 ml of cDNA in a total volume of 25 ml. Primer and probe sequences were as follows:
Western blot analysis Total protein was isolated from epidermis and tumor samples (DMBA-TPA-derived papillomas and carcinomas) with Triton-X buffer. Samples were electrophoresed on a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel and electroblotted onto polyvinylidene difluoride membranes (Pierce, Rockford, IL, USA). Immunoblot analysis for EP2, VEGF, and anti-flag, using 50 mg, 100 and 50 mg of protein was performed as follows. Blots were blocked for 1 h in 5% nonfat milk in phosphate-buffered saline (PBS) containing 0.1% Tween 20-Tris-buffered saline (TTBS) and immunostained with antibodies (EP2, VEGF, anti-flag) specific for all the proteins listed. Incubation of primary antibodies for EP2 (1:500) or VEGF (1:100) or anti-flag (1:500) was followed by incubation with secondary antibodies, that is, anti-rabbit (1:2000), antigoat (1:1000), and anti-mouse (1:2000), respectively. The blots were stripped and immunostained with antibodies against b-actin as loading controls. The specific bands were detected by an enhanced chemiluminescence kit (Perkin-Elmer Life Sciences, Boston, MA, USA).
Generation of EP2 TG mice
Human EP2 full-lengh cDNA was inserted downstream of the BK5 promotor and rabbit b-globin intron and flag-tag followed by the SV40 poly A signal. This BK5.EP2 construct was microinjected into fertilized eggs of FVB mice, which were transferred to pseudopregnant female mice. This was carried out by the Science Park Transgenic Animal Facility. The heterozygous offspring resulting from crossing of this founder to WT FVB mice was used for sibling mating to generate homozygous transgenic (TG) mice. Homozygous ( þ / þ ) EP2 TG mice were used for this study. Genotypes of the mice were confirmed by PCR analysis using the oligomers 5 0 -CTT TAT AAT CAA GGT CAG CCT G-3 0 and 5 0 -ACC TCA TTC TCC TGG CTA TCA T-3 0 . Wild-type FVB mice were used as controls. FVB mice were purchased from Harlan (Indianapolis, IN, USA). All mice were maintained at Science Park and housed in an air conditioned facility which is AAALAC accredited.
Cyclic adenosine monophosphate analysis Cyclic adenosine monophosphate measurement was carried out using a kit from Perkin-Elmer Life Sciences. Dorsal epidermis from EP2 TG and WT mice was removed quickly 1 h after treatment with 100 mM PGE2 with as little manipulation as possible and immediately snap frozen in liquid nitrogen, placed in ice cold 0.05 M Tris-HCl buffer (pH 7.4) containing 5 mg/ml indomethacin and stored at À701C. For some groups of mice, the adenylate cyclase inhibitor SQ 22 536 (100 mM) was topically applied 30 min before the application of PGE2. Calculation of cAMP concentrations (pmol/mg protein) was based on a standard curve for each experiment.
Tumor experiments
Thirty 6-8-week-old female homozygous EP2 TG mice and WT mice (FVB strain) were initiated topically on shaved dorsal skin with 100 mg of DMBA in 200 ml of acetone. At 2 weeks after initiation, the mice were topically treated with 2.5 mg TPA in 200 ml acetone twice a week for a period of 28 weeks. Tumor incidence and tumor multiplicity were recorded weekly. Tumor multiplicity was calculated as the average number of skin tumors per mouse. Tumor incidence was calculated as the percentage of mice with skin tumors. Tumor size was measured with calipers at the end of the experiments. Tumor type was defined by histopathology.
5-bromo-2-deoxyuridine (BrdU) incorporation
Three each of 8-week-old EP2 TG mice and WT mice were shaved 2 days before treatment with TPA (2.5 mg/200 ml) acetone. 5-bromo-2-deoxyuridine (0.1 mg/g body weight) was injected intraperitoneally 1 h before killed. The mice were euthanized 18 h after a single or four (twice a week) TPA treatments and their dorsal skins were removed, fixed in formalin and processed for paraffin embedding and immunohistochemical staining with a monoclonal rat anti-BrdU antibody (Accurate Chemical and Scientific Corp.) at a 1:500 dilution for 1 h at room temperature and a rabbit anti-mouse antibody (Accurate Chemical and Scientific Corp.) as secondary antibody at a 1:250 dilution for 15 min at room temperature by the Histology Core of the Science Park Research Division. 5-bromo-2-deoxyuridine positive and negative basal cells are counted in three to five randomly selected areas of each skin section (3-4 sections per mouse) and the mean percentage of BrdU-positive cells and standard deviation (s.d.) for each treatment group were determined.
Hyperplasia
Hyperplasia was assessed in three each of 8-week-old EP2 TG mice and WT mice 48 h after treatment with acetone or TPA (2.5 mg/200 ml acetone). The thickness of the epidermis (mm) was measured using an image system (Nikon ACT-1). The onscreen measurements of epidermis were obtained as raw data, and the actual thickness of epidermis was calculated by dividing the raw data by the magnification ( Â 650) in 15 fields per section.
Cell culture
Primary skin keratinocytes from newborn EP2 TG mice and WT mice were prepared as described by Yuspa and Harris (1974) . Briefly, 1-2-day-old mouse pups were euthanized on ice and washed in 75% ethanol. The skin was stripped off and floated on 0.25% trypsin overnight at 41C. The epidermis was separated from the dermis and chopped in Waymouth's medium containing 1.2 mM calcium and 10% fetal bovine serum. The cells were filtered through a sterilized mesh and plated at 2 Â 10 6 cells/dish for most purposes. Cells were incubated at 371C with 5% CO 2 for 2 h in Waymouth's medium to allow them to attach to the plate. Cells were then washed with PBS and grown in keratinocyte growth medium (KGM, a serum-free medium containing 0.03 mM calcium, Cambrex, Walkers, MD, USA) at 371C with 5% CO 2 for experimental use and treated with 0.2% vehicle (methanol) or PGE2.
3
H-thymidine incorporation assay Primary cultures of skin keratinocytes from WT and EP2 TG mice at about 85-90% confluence in six-well plates were treated in triplicate with 0-30 mM PGE2 (Cayman Chemical) for 20 h and pulsed with 1 mCi/ml 3 H-thymidine 2 h before harvest. Cells were then washed with ice-cold PBS 2 Â and icecold 10% trichloroacetic acid 3 Â . Cells were lysed with 0.3 N NaOH, 1% SDS and the 3 H-thymidine incorporated by cells was counted in a scintillation counter and normalized to protein concentration. Protein concentration was determined with the BCA kit (Bio-Rad, Richmond).
Immunohistochemistry
At the end of the experiments tumors were removed from the animals, fixed immediately in formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin (H&E) for light microscopy. The Science Park Histology Service performed the work involved in embedding, sectioning and staining. All tissues were examined histologically to determine whether the epithelium was normal, dysplastic, invasive, or had the characteristic papilloma or carcinoma patterns. Angiogenesis was assessed by staining of endothelial cells in papilloma and SCC samples of similar sizes, 7 Â TPA and DMBA-TPA-treated skins from WT and EP2 TG mice with an anti-CD-31 antibody (Santa Cruz BioTechnology, Santa Cruz, CA) at a 1:400 dilution for 1 h at room temperature and an anti-rat IgG antibody (Accurate Chemical and Scientific Corp.) as secondary antibody at a 1:200 dilution for 30 min at room temperature. Six-to 8-week-old female homozygous EP2 TG mice and WT mice were initiated topically on dorsal skin with 100 mg with DMBA in 200 ml of acetone (six each per treatment group). At 2 weeks after initiation, the mice were topically treated with 2.5 mg TPA in 200 ml acetone twice a week for a period of 6 weeks. To stain 7 Â TPA-treated skins from WT and EP2 TG mice with an anti-CD-31 antibody, groups of six mice per treatment group were treated three times weekly for 2 weeks and killed 48 h after the last treatment with 2.5 mg of TPA. The number of CD31 vessels was counted in 15 fields and eight fields per section for skins and tumors, respectively, at Â 400 magnification. Apoptosis was determined by anticaspase-3 antibody (R&D Systems, Minneapolis, MN, USA) at a 1:2000 dilution for 30 min at room temperature and a goat anti-rabbit IgG antibody as secondary antibody at a 1:500 dilution for 30 min at room temperature staining in papilloma and SCC samples of similar sizes from WT and EP2 TG mice. The number of apoptotic positive cells was counted in eight fields at a magnification of Â 400. Inflammation was assessed by antibody staining of macrophages at a 1:100 dilution for 2 h at room temperature and a rabbit anti-rat IgG antibody as secondary antibody at a 1:200 dilution for 30 min at room temperature in three each of 8-week-old EP2 TG mice and WT mice treated with acetone or TPA for 48 h. The number of macrophage-positive cells was counted in 15 fields at Â 400 magnification.
Statistical analysis
Data are shown as the mean7s.d. Statistical differences between means were determined using one-way ANOVA using SPSS 10 (SPSS Mac V.10, SPSS, Chicago, IL, USA).
